InflaRx (NASDAQ:IFRX) Upgraded to Strong-Buy at Raymond James Financial

InflaRx (NASDAQ:IFRX) was upgraded by stock analysts at Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a report released on Wednesday, Marketbeat.com reports. The firm presently has a $9.00 price target on the stock. Raymond James Financial’s target price would indicate a potential upside of 270.37% from the stock’s current price.

IFRX has been the subject of a number of other reports. Guggenheim reiterated a “buy” rating and set a $14.00 price objective on shares of InflaRx in a research note on Tuesday, April 21st. Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Friday, March 27th. HC Wainwright raised their price objective on shares of InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday. Finally, Oppenheimer began coverage on shares of InflaRx in a research note on Friday, April 24th. They set an “outperform” rating and a $5.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

InflaRx Stock Performance

NASDAQ IFRX opened at $2.43 on Wednesday. The business’s fifty day moving average is $1.29 and its 200 day moving average is $1.16. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $2.95. The company has a market capitalization of $175.66 million, a PE ratio of -3.42 and a beta of 2.42.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. On average, sell-side analysts forecast that InflaRx will post -0.59 EPS for the current year.

Institutional Trading of InflaRx

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC increased its holdings in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares during the last quarter. Boothbay Fund Management LLC boosted its stake in shares of InflaRx by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock worth $235,000 after purchasing an additional 17,056 shares during the period. Concurrent Investment Advisors LLC boosted its position in shares of InflaRx by 56.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after buying an additional 19,200 shares during the period. Eversept Partners LP grew its stake in shares of InflaRx by 1.5% during the fourth quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock valued at $1,775,000 after buying an additional 26,677 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of InflaRx by 29.1% in the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after buying an additional 42,489 shares during the period. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.